The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.

For individual iodine-131 ((131)I) treatment dosage calculations, most physicians use the 'standard dosage formula', which requires measurements of thyroid volume and thyroidal (131)I uptake. The effective half-life of (131)I (T(eff)) is then unjustifiably ignored. Evidence is presented that the 5/24h (131)I uptake ratio can be used as a surrogate parameter for T(eff), and that it is a determinant of the (131)I therapy outcome for patients with Graves' disease.

No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Purpose: To compare disease-specific survival and recurrence-free survival (RFS) after successful (131)I ablation in patients with differentiated thyroid carcinoma (DTC) between those defined before ablation as low-risk and those defined as high-risk according to the European Thyroid Association 2006 consensus statement.

Methods: Retrospective data from three university hospitals were pooled. Of 2009 consecutive patients receiving ablation, 509 were identified as successfully ablated based on both undetectable stimulated serum thyroglobulin in the absence of antithyroglobulin antibodies and a negative diagnostic whole-body scan in a follow-up examination conducted 8.

The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.

Introduction: The aim of the study was to compare the success rate of an uptake-related ablation protocol in which the dose depends on an I-131 24-h neck uptake measurement and a fixed-dose ablation protocol in which the dose depends on tumour stage.

Methods: All differentiated thyroid carcinoma patients with M0 disease who had undergone (near-) total thyroidectomy followed by I-131 ablation were included. In the uptake-related ablation protocol, 1100 (uptake >10%), 1850 (uptake 5-10%) and 2800 MBq (uptake <5%) were used.

I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer.

Focal I-131 accumulation is generally a reliable indicator of functioning normal thyroid tissue or a differentiated thyroid cancer metastasis. However, physiologic accumulation of activity may also be observed in organs such as the intestinal tract, liver, and salivary glands. Extrathyroidal I-131 accumulation has been reported in various sites, such as ectopic gastric mucosa, gastrointestinal and urinary tract abnormalities, cysts (mammary, liver, kidney, and ovaries), and inflammation and infection foci.

Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation.

Aim: The aim of this study was to assess the efficacy of treatment of patients with papillary thyroid carcinoma (PTC) and lymph node metastases at the time of diagnosis and its influence on the course of the disease.

Methods: It is a retrospective review of all 51 patients with PTC and histologically proven lymph node metastases treated with I-131 ablation in our center between January 1990 and January 2003. Patients were considered disease-free if during follow-up thyroglobulin levels were undetectable and scintigraphy with 370 MBq (131)I was negative during thyroid-stimulating hormone stimulation.

Use of radiopharmaceuticals for diagnosis, treatment, and follow-up of differentiated thyroid carcinoma.

In 1942, Dr. Seidlin of the Memorial Hospital in New York was faced with a 51-year- old patient who had undergone a thyroidectomy in 1923 [1]. At the time, the histologic diagnosis was a 'malignant adenoma' of the thyroid.

Suspected thyroid stunning after radioiodine-131 scanning in a patient with a diffuse goiter.

A case of suspected thyroid stunning is presented in a previously hyperthyroid patient with a diffuse goiter, who had undergone a 185 MBq (131)I-NaI thyroid scan shortly before a (99m)Tc-pertechnetate scan. A less likely alternative hypothesis is the development of early hypothyroidism, 3.5 weeks after a modest (131)I dose.

Comparison of methods for thyroid volume estimation in patients with Graves' disease.

Individualised dosage models are frequently applied for radioiodine therapy in patients with Graves' hyperthyroidism, especially in Europe. In these dosage schemes the thyroid volume is an important parameter. Thyroid volume determinations are usually made with ultrasonography or with thyroid scintigraphy, although the accuracy of planar scintigraphy for this purpose is not well established.